Selection of a novel CD19 aptamer for targeted delivery of doxorubicin to lymphoma cells

2Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

CD19 is overexpressed in most human B cell malignancies and considered an important tumor marker for diagnosis and treatment. Aptamers are oligonucleotides that may potentially serve as tumor-homing ligand for targeted cancer therapy with excellent affinity and specificity. In this study, we selected a novel CD19 aptamer (LC1) that was a 59-nucleotide single strand DNA. The aptamer could bind to recombinant CD19 protein with a K d of 85.4 nM, and had minimal cross reactivity to bovine serum albumin (BSA) or ovalbumin (OVA). Moreover, the aptamer was found capable of binding with the CD19-positive lymphoma cells (Ramos and Raji), but not the CD19-negative cell lines (Jurkat and NB4). An aptamer-doxorubicin complex (Apt- Dox) was also formulated, and selectively delivered doxorubicin to CD19-positive lymphoma cells in vitro. The results indicate that aptamer LC1 can recognize CD19- positive tumor cells and may potentially function as a CD19-targeting ligand.

Author supplied keywords

Cite

CITATION STYLE

APA

Hu, Y., Li, X., An, Y., Duan, J., & Yang, X. D. (2018). Selection of a novel CD19 aptamer for targeted delivery of doxorubicin to lymphoma cells. Oncotarget, 9(42), 26605–26615. https://doi.org/10.18632/oncotarget.24902

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free